CervoMed Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRVO research report →
Range $7 – $7
Price Chart
About the company
CervoMed Inc. , a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.
- CEO
- John J. Alam
- IPO
- 2008
- Employees
- 15
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on CRVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.09M
- P/E
- -0.53
- PEG
- -0.71
- P/S
- 0.00
- P/B
- 1.27
- EV/EBITDA
- -0.56
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -164.95%
- ROIC
- -168.39%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-28,294,877
- Net Income
- $-26,966,367-65.5%
- EPS
- $-2.98-47.5%
- OCF Growth
- -41.9%
- FCF Growth
- -41.9%
- 52W High
- $10.00
- 52W Low
- $1.27
- 50D MA
- $2.24
- 200D MA
- $3.19
- Beta
- -3.99
- RSI (14)
- 37
- Avg Volume
- 489.10K
No earnings-call transcripts are available for CRVO yet.
- Free Float
- 63.5%
- Shares Outstanding
- 15.13M
- Float Shares
- 9.61M
of shares held by institutions
37 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Woodline Partners LP | 688.99K | ▲ 688.99K |
| Vanguard Group Inc | 354.95K | ▲ 11.49K |
| Vanguard Capital Management LLC | 316.20K | 0 |
| Sabby Management, LLC | 199.68K | ▼ 49.20K |
| Geode Capital Management, LLC | 92.01K | ▲ 25.08K |
| Blackrock, Inc. | 79.66K | ▲ 25.82K |
| Vanguard Fiduciary Trust Co | 61.52K | ▲ 25.36K |
| Citigroup Inc | 39.33K | ▲ 38.67K |
| Citizens Financial Group Inc/Ri | 37.48K | 0 |
| Savvy Advisors, Inc. | 25.92K | 0 |
| Thompson Davis & Co., Inc. | 25.90K | ▼ 3.85K |
| Virtu Financial LLC | 24.09K | ▲ 24.09K |
Held by 24 ETFs
Biggest fund positions in CRVO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | ALAM JOHN J | buy | 76,319 |
| Nov 18, 26 | ALAM JOHN J | buy | 23,681 |
| Oct 22, 26 | Blackburn Kelly | other | 19,100 |
| Oct 22, 26 | De Rosch Mark | other | 19,100 |
| Oct 22, 26 | Winton Matthew | other | 19,100 |
| Jun 11, 26 | BOGER JOSHUA S | buy | 955,414 |
| Jun 11, 26 | BOGER JOSHUA S | buy | 955,414 |
| Jun 11, 26 | BOGER JOSHUA S | buy | 955,414 |
| Jun 8, 26 | ZAVRL FRANK | other | 8,150 |
| Jun 8, 26 | Sabbagh Marwan | other | 8,150 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRVO coverage
Recent articles, reports, and earnings notes.
No research on CRVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRVO report →CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
globenewswire.com · Nov 16
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com · Nov 9
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
globenewswire.com · Oct 29
CervoMed Shows Progress in Treating Rare Aphasia Condition
benzinga.com · Oct 12
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright
defenseworld.net · Oct 5
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages
defenseworld.net · Oct 3
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
globenewswire.com · Sep 28
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
globenewswire.com · Sep 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.